Curanex Pharmaceuticals Inc Common Stock (CURX)

About CURX

Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients with inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma Inc. and changed its name to C…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

6

Website

www.curanexpharma.com/

Fundamentals

1-day range

$4.68$4.95

Market cap

$5.53M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-6.75

Dividend yield

—

Beta

0.56

Avg. volume

20.4K

Curanex Pharmaceuticals Inc Common Stock Competitors

Chosen by industry and closest market cap.

• CURX

  Curanex Pharmaceuticals Inc Common Stock

  $4.62

  ▼ 4.35%
  Market cap $5.53MP/E —
  $3.58$16.94
• NCNA

  NuCana plc American Depositary Share

  $0.99

  ▼ 2.94%
  Market cap $5.66MP/E 0.01
  $0.9484$6.1
• BGMS

  Bio Green Med Solution Inc. Common Stock

  $0.91

  ▲ 9.64%
  Market cap $5.35MP/E —
  $0.5664$6.11
• GOVX

  GeoVax Labs Inc. Common Stock

  $0.238

  ▼ 7.75%
  Market cap $5.31MP/E —
  $0.24$15.75
• SILO

  Silo Pharma Inc. Common Stock

  $1.18

  ▼ 1.67%
  Market cap $5.85MP/E —
  $1.3$10.44
• ERNA

  Ernexa Therapeutics Inc. Common Stock

  $2.09

  ▼ 3.69%
  Market cap $5.09MP/E —
  $2.01$71.5
• PULM

  Pulmatrix Inc. Common Stock

  $1.36

  ▼ 3.55%
  Market cap $6.06MP/E —
  $1.16$5.24

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

327.8K

Total value held

$167.6K

Institutional holders

8